A Review on Nanotechnology and Histotripsy for Cancer Treatment

Ashish K. Parashar, Lalit K. Tyagi, Vandana Arora, Neelam Jain, Neeraj Jain, Shubhrat Maheshwari
*[1, 2] Lloyd Institute of Management and Technology, Greater Noida, Uttar Pradesh, India-201306
[3]Faculty of Pharmacy, Oriental University, Indore-453555, M.P., India.

[4]Teerthankar Mahaveer College of Pharmacy, TMU, Moradabad- 244001, U.P., India.
[5]Faculty of Pharmaceutical sciences Rama University, Mandhana, Kanpur-209217, U.P., India.

Abstract
Nanotechnology and histotripsy are two emerging fields in cancer treatment that hold great promise for improving patient outcomes. This review article aims to provide an overview of the latest advancements in these fields and their potential applications in the treatment of various types of cancer. Nanotechnology involves the manipulation of matter at an atomic and molecular scale to create materials with unique properties. In the context of cancer treatment, nanotechnology offers the potential for targeted drug delivery, imaging, and therapy. On the other hand, histotripsy is a non-invasive therapeutic technique that uses focused ultrasound to mechanically fractionate tissues, including cancerous tumors, without the need for surgery or radiation. This review article will delve into the recent developments in nanotechnology-based cancer therapies, such as the use of nanoparticles for drug delivery and imaging, as well as the applications of histotripsy in tumor ablation and tissue disruption. Furthermore, the potential synergistic effects of combining nanotechnology and histotripsy for enhanced cancer treatment will be explored. By providing a comprehensive summary of the latest research and clinical applications in these fields, this review aims to contribute to the understanding of how nanotechnology and histotripsy can revolutionize cancer treatment and improve patient outcomes.

Keywords: Cancer, Nanotechnology, Histotripsy, Drug delivery, Targeting, Imaging.
DOI Number: 10.48047/Nq.2022.20.17.Nq880302 **Neuroquantology 2022; 20(17):2364-2375**

Introduction

Cancer continues to be a significant global health concern, and the search for innovative and effective treatment strategies remains a top priority in medical research. In recent years, nanotechnology and histotripsy have emerged as promising areas of focus for combating cancer [1]. Nanotechnology, with its ability to engineer materials at the molecular level, offers the potential for precise and targeted cancer therapy, while histotripsy, utilizing focused ultrasound, presents a non-invasive alternative to traditional cancer treatment methods [2-3].

By examining the synergistic effects of combining these two cutting-edge technologies, we hope to present a comprehensive overview of the potential impact of nanotechnology and histotripsy on cancer treatment [4]. This review aims to provide valuable insights into the ongoing efforts to revolutionize cancer therapy and improve patient outcomes.

In recent years, nanotechnology has emerged as a promising approach for cancer therapy [5]. By utilizing nanoparticles as carriers, drugs can be delivered in a targeted and controlled manner to cancer cells. This approach offers several advantages, including increased drug concentration at the tumor site, improved biocompatibility, and enhanced selectivity [6]. Additionally, nanotheranostics, which combines therapeutics and diagnostics, enables simultaneous monitoring of treatment response and delivery of active materials to the desired area of the body. Furthermore, nanocarriers such as hyaluronic acid-based nanoparticles have shown promise in targeted drug delivery to tumors with increased expression of specific receptors, such as the CD44 receptor recognized by hyaluronic acid [7-8]. Histotripsy, on the other hand, utilizes focused ultrasound waves to selectively disrupt tumor tissues. Recent studies have demonstrated the potential of histotripsy in achieving complete tumor ablation while minimizing damage to surrounding healthy tissues [9]. This non-invasive approach to cancer treatment shows great promise for reducing the side effects often associated with traditional treatments such as surgery and radiation therapy. Furthermore, the ability to precisely target and disrupt tumor tissues without the need for incisions or anesthesia makes histotripsy an attractive option for patients and clinicians alike [10].

The combination of nanotechnology and histotripsy presents exciting possibilities for advancing cancer treatment [11-12]. By integrating nanocarriers with histotripsy, targeted drug delivery can be further optimized to enhance the effectiveness of cancer therapies while minimizing systemic toxicity. Additionally, the use of nanoparticles in conjunction with histotripsy may allow for real-time monitoring of treatment response, providing valuable feedback to clinicians and researchers [13].

In this review, we will explore the latest developments in nanotechnology and histotripsy for cancer treatment, taking a closer look at the advancements in targeted drug delivery, imaging techniques, and therapeutic applications. Additionally, we will examine the growing body of evidence supporting the use of histotripsy for tumor ablation and tissue disruption, shedding light on its potential as a vital component in the fight against cancer.

Nanotechnology and Cancer Therapy

Nanotechnology has emerged as a promising tool in cancer therapy, offering several advantages for targeted drug delivery and improved treatment outcomes [14]. It allows for the precise delivery of active materials to specific areas of the body, enhancing the efficacy of cancer treatments while minimizing systemic toxicity. The use of nanoparticles as carriers for chemotherapy drugs has shown promise in increasing drug concentration at the target site and improving selectivity [15]. Furthermore, nanocarriers can be designed to release drugs in response to specific stimuli, such as pH levels or temperature changes, further enhancing their targeted delivery capabilities [16].

Targeted Drug Delivery

Nanoparticles have garnered significant attention as carriers for targeted drug delivery in cancer therapy [17]. Their ability to encapsulate and deliver therapeutic agents directly to tumor sites can enhance treatment efficacy while minimizing off-target effects. Various types of nanoparticles, including liposomes, polymeric nanoparticles, and inorganic nanoparticles, offer unique advantages in terms of drug loading capacity, stability, and release kinetics [18-19]. Additionally, surface modifications of nanoparticles can be tailored to specifically target cancer cells, promoting selective uptake and retention within the tumor microenvironment [20].

For example, gold nanoparticles have shown promise in targeted drug delivery due to their unique physicochemical properties and ease of surface functionalization [21]. By conjugating targeting ligands, such as antibodies or peptides, to the surface of gold nanoparticles, researchers have been able to enhance their affinity for cancer cells and improve their accumulation at tumor sites [22]. Moreover, the small size of nanoparticles allows for efficient penetration into tumor tissues, overcoming biological barriers and improving drug distribution.

Nanotheranostics and Cancer Diagnostics

Nanotheranostics, which combines therapeutics and diagnostics, has emerged as a valuable approach in cancer treatment [5]. This integrated approach allows for simultaneous imaging of tumors and targeted delivery of therapeutics, leading to improved treatment monitoring and personalized medicine [23]. Nanotheranostics employs various imaging techniques, such as magnetic resonance imaging, computed tomography, positron emission tomography, and optical imaging, to visualize and characterize cancer cells and tissues [24]. These imaging techniques enable the detection of tumors, assessment of their size and location, and evaluation of treatment response [25]. Furthermore, nanotheranostics has the potential to revolutionize cancer diagnostics by providing a platform for early detection and personalized treatment strategies. For instance, the development of multifunctional nanoparticles capable of simultaneous imaging and targeted drug delivery has opened new possibilities for real-time monitoring of treatment response and disease progression [26]. These nanoparticles can be engineered to carry both imaging agents and therapeutic drugs, allowing clinicians to visualize the tumor and its response to treatment while delivering tailored therapies based on the observed changes [27].

An example of nanotheranostics in cancer diagnostics is the utilization of iron oxide nanoparticles for magnetic resonance imaging and as carriers for anticancer drugs [28]. Iron oxide nanoparticles not only serve as contrast agents for visualizing tumors with high sensitivity in MRI but also enable the targeted delivery of therapeutic agents to the tumor site [29]. This dual-functionality of iron oxide nanoparticles exemplifies the potential of nanotheranostics in improving cancer diagnosis and treatment.

In the field of cancer diagnostics, nanotheranostics has also paved the way for the development of novel biosensors and imaging probes for early cancer detection [30-31]. By incorporating nanoparticles into diagnostic assays and imaging modalities, researchers have been able to achieve enhanced sensitivity and specificity in detecting cancer biomarkers and cellular abnormalities. The use of nanoscale materials in cancer diagnostics holds great promise for improving the accuracy of early cancer detection, thereby enabling timely intervention and improved patient outcomes [32-33].

Nanotheranostics and cancer diagnostics represent innovative and promising approaches in the field of cancer research and treatment. The integration of nanotechnology with advanced imaging and therapeutic modalities has the potential to transform the way cancer is diagnosed, monitored, and treated, ultimately leading to better clinical outcomes and improved quality of life for patients [34].

Therapeutic Applications

Beyond targeted drug delivery and imaging, nanotechnology has paved the way for innovative therapeutic applications in cancer treatment. Nanoparticle-based photothermal therapy, utilizing light-absorbing nanoparticles to generate localized heat and destroy cancer cells, has shown potential as a minimally invasive treatment modality [35]. Moreover, the development of multifunctional nanoparticles, capable of carrying therapeutic payloads and simultaneously performing imaging functions, holds promise for personalized and precise cancer therapy [36].

Nano-immunotherapy is another emerging therapeutic application of nanotechnology in cancer treatment [37]. By leveraging the unique properties of nanoparticles, researchers are exploring the use of nanomaterials to modulate the immune system and enhance the body's ability to recognize and attack cancer cells [38]. For example, nanoscale vaccine platforms have been designed to deliver tumor-associated antigens and immunomodulatory agents, stimulating a targeted immune response against specific cancer cells. These nano-immunotherapies have the potential to improve the efficacy of cancer immunotherapy and overcome immune evasion mechanisms employed by tumors [39-42].

Furthermore, the field of RNA interference therapeutics has been revolutionized by the development of nanoparticles for efficient delivery of small interfering RNA (siRNA) molecules to silence genes involved in cancer progression [43-44]. Nanoparticle-based RNAi therapeutics offer a promising approach to selectively inhibit oncogenes and tumor-promoting pathways within cancer cells, potentially leading to enhanced treatment outcomes and reduced systemic side effects [45].

Additionally, nanotechnology has enabled the advancement of gene editing technologies for precise manipulation of cancer-related genes. Nanoparticle-mediated delivery of gene editing tools, such as CRISPR-Cas9, to target and modify specific genetic mutations in cancer cells holds great potential for developing personalized and targeted cancer therapies [42, 46-47].

The therapeutic applications of nanotechnology in cancer treatment encompass a diverse range of innovative approaches, from nano-immunotherapy and RNA interference to targeted gene editing [48]. These cutting-edge advancements hold great promise for revolutionizing the landscape of cancer therapy, providing more effective and personalized treatment options for patients [49].

Introduction to Histotripsy in Cancer Treatment

In recent years, histotripsy has gained attention as a non-invasive therapeutic modality for cancer treatment. Histotripsy is a form of ultrasound therapy that utilizes acoustic cavitation to mechanically fractionate targeted tissue, including cancerous tumors, into acellular debris [50]. This unique mechanism of action distinguishes histotripsy from other therapeutic modalities and offers several potential advantages in the field of oncology [12].

One of the key advantages of histotripsy is its non-invasive nature, as it does not require surgical incisions or the insertion of needles or probes into the body [51]. This minimally invasive approach can reduce the risk of complications and infections, improve patient comfort, and enable quicker recovery compared to traditional surgical interventions [52].

In addition to its non-invasiveness, histotripsy holds promise for precise and targeted treatment of solid tumors. By leveraging the ability to focus ultrasound energy with extreme precision, histotripsy offers the potential to selectively ablate tumor tissues while sparing surrounding healthy structures. This targeted approach may minimize damage to adjacent critical organs and tissues, reducing the risk of adverse effects commonly associated with conventional cancer treatments [53].

Furthermore, histotripsy has the potential to synergize with other therapeutic modalities, such as chemotherapy or immunotherapy. The non-thermal nature of histotripsy-induced tissue ablation allows for the preservation of molecular and cellular components within the treated area, which may enhance the immunogenicity of the tumor microenvironment [54]. This, in turn, could potentially augment the systemic anti-tumor immune response, leading to improved treatment outcomes and long-term control of the disease [55].

The unique capabilities and potential synergies of histotripsy in cancer treatment underscore its potential as a promising modality in the evolving landscape of oncology [56]. As research and technological advancements continue to unfold, histotripsy holds the promise of offering novel strategies for combating cancer while minimizing the burden on patients.

Advancements in Histotripsy for Cancer Treatment

Histotripsy, with its non-invasive approach and precise tissue disruption capabilities, has garnered significant interest as a viable alternative to traditional cancer treatment methods [57]. Recent advancements in focused ultrasound technology have led to improved targeting of cancerous tissues and enhanced efficiency in tumor ablation. The ability of histotripsy to selectively disrupt tumors while preserving surrounding healthy tissues offers a favorable safety profile and reduced risk of adverse effects compared to invasive procedures [58].

Targeted Tumor Ablation

Histotripsy has demonstrated remarkable potential for targeted and complete tumor ablation in preclinical and clinical studies [10]. By utilizing focused ultrasound waves, histotripsy effectively breaks down cancerous tissues without the need for surgical incisions, providing a minimally invasive yet highly effective treatment option. The precision of histotripsy in targeting tumors holds promise for reducing recurrence rates and improving long-term outcomes for cancer patients [12].

Recent studies have highlighted the efficacy of histotripsy in achieving precise and complete ablation of tumors, particularly in challenging anatomical locations. For instance, in a study published in the Journal of Therapeutic Ultrasound, researchers reported successful histotripsy treatment of pancreatic tumors, a notoriously difficult target due to its proximity to critical structures and vasculature [59]. The non-invasive nature of histotripsy and its ability to selectively target and ablate pancreatic tumors without causing collateral damage to surrounding organs signify a major advancement in the field of pancreatic cancer treatment [60].

Furthermore, advancements in histotripsy technology have expanded its applicability to a wide range of solid tumors, including liver, kidney, and prostate tumors. Clinical trials evaluating the use of histotripsy for liver cancer have demonstrated its potential for achieving complete tumor necrosis while preserving the vital structures of the liver, offering a favorable safety profile and reducing the risk of post-treatment complications [61].

The precise targeting capabilities of histotripsy also extend to the treatment of prostate tumors, where the preservation of neurovascular bundles is critical to maintaining urinary and sexual function [62]. Research studies have shown that histotripsy can selectively ablate prostate tumors while minimizing damage to adjacent neurovascular bundles, potentially addressing the quality of life concerns commonly associated with conventional prostate cancer treatments.

Moreover, the emerging applications of histotripsy in kidney cancer treatment have shown promising results in achieving focal tumor ablation with preservation of renal function. The ability to spare healthy renal parenchyma while effectively treating localized kidney tumors represents a significant advancement in the management of renal cell carcinoma, offering the potential for improved patient outcomes and reduced risk of post-treatment renal insufficiency [63].

The advancements in histotripsy technology, coupled with its targeted and non-invasive nature, position it as a valuable addition to the armamentarium of cancer treatment modalities. As ongoing research and clinical trials continue to elucidate the full potential of histotripsy in diverse oncological scenarios, its role in revolutionizing the landscape of cancer therapy becomes increasingly evident [64].

Synergistic Integration of Nanotechnology and Histotripsy

The integration of nanotechnology with histotripsy opens new frontiers in cancer treatment by harnessing the strengths of both techniques. By combining nanocarriers with histotripsy, the precise delivery of therapeutic agents to tumor sites can be further refined, optimizing treatment efficacy while minimizing systemic toxicity. Additionally, the real-time monitoring capabilities offered by nanoparticles can complement the precise tissue disruption of histotripsy, providing valuable feedback on treatment response and guiding the refinement of therapeutic strategies [21].

The synergy between nanotechnology and histotripsy holds great promise in revolutionizing cancer treatment through the precise delivery of therapeutic agents to tumor sites [65]. Recent advancements in the field have demonstrated the potential of nanotechnology-enabled precision targeting to optimize treatment efficacy while minimizing systemic toxicity.

Nanoparticles, specifically designed to encapsulate chemotherapeutic agents or immunomodulators, can be engineered to selectively accumulate within tumor tissues through passive or active targeting mechanisms. When combined with histotripsy, these nanoparticle-based carriers can be guided to the tumor site using focused ultrasound, allowing for localized and controlled release of therapeutic payloads. This approach minimizes off-target effects and systemic exposure, enhancing the therapeutic index of conventional chemotherapy or immunotherapy while reducing the risk of toxicity to healthy tissues [66-67].

Case studies have highlighted the successful integration of nanotechnology with histotripsy for precision targeting of solid tumors. In a clinical trial investigating the use of nanoparticle-loaded microbubbles in conjunction with histotripsy for the treatment of breast cancer, researchers observed enhanced accumulation of the therapeutic payload within the tumor microenvironment [68]. The focused ultrasound energy from histotripsy facilitated the release of the encapsulated agents from the nanoparticles, resulting in a localized and potent anti-tumor effect while sparing surrounding healthy tissues. This nanotechnology-enabled precision targeting approach not only improved the response to treatment but also minimized the systemic side effects commonly associated with systemic chemotherapy regimens [69].

Furthermore, the real-time monitoring capabilities offered by nanoparticle-based contrast agents have complemented the precision tissue disruption of histotripsy, providing valuable insights into treatment response and guiding the optimization of therapeutic strategies. By incorporating imaging probes within the nanoparticles, clinicians have been able to visualize the extent of tumor ablation and assess the immediate post-treatment effects, enabling personalized treatment adjustments and ensuring thorough tumor eradication [70].

The successful integration of nanotechnology with histotripsy in cancer treatment not only signifies a paradigm shift in precision medicine but also underscores the potential for personalized and targeted therapeutic approaches. As ongoing research continues to unravel the synergistic benefits of this integration, the convergence of nanotechnology and histotripsy stands poised to redefine the landscape of cancer therapy, offering new hope for improved patient outcomes and long-term disease control.

One example of the application of nanotechnology-enabled precision targeting is the targeted delivery of chemotherapeutic agents to solid tumors using nanoparticle-based carriers in conjunction with histotripsy. For instance, in a preclinical study focusing on the treatment of lung cancer, researchers engineered nanoparticles to encapsulate a potent chemotherapeutic drug and utilized histotripsy for precise tumor ablation [71-72]. The focused ultrasound energy from histotripsy facilitated the release of the chemotherapeutic payload from the nanoparticles specifically within the tumor microenvironment, leading to enhanced tumor cell killing while minimizing systemic exposure and off-target effects [73].

Another application lies in the real-time monitoring of treatment response and tumor ablation using nanoparticle-based contrast agents. In a clinical trial involving the treatment of colorectal cancer liver metastases, clinicians utilized nanoparticle-loaded contrast agents in conjunction with histotripsy to visualize the extent of tumor ablation and assess the immediate post-treatment effects. The integration of nanoparticle-based contrast agents with histotripsy allowed for precise visualization of the treatment site, enabling clinicians to make personalized treatment adjustments and ensure thorough tumor eradication while minimizing damage to healthy liver tissue [74].

These examples demonstrate the practical implementation of the synergistic integration of nanotechnology with histotripsy in cancer therapy, showcasing their potential to revolutionize treatment strategies and improve patient outcomes. The utilization of nanoparticles for precise drug delivery and real-time monitoring, in combination with the tissue disruption capabilities of histotripsy, represents a promising approach to personalized and targeted cancer therapy. Further exploration and development of such applications hold significant promise for advancing the field of oncology and addressing the evolving needs of cancer patients.

Future Scope

As the field of oncology continues to advance, the synergistic integration of nanotechnology and histotripsy presents a promising avenue for future developments in cancer therapy. Ongoing research and clinical trials are poised to further elucidate the potential of this integration, paving the way for customized and targeted therapeutic approaches that prioritize both efficacy and patient safety.

One area of future exploration lies in the refinement of nanoparticle design and engineering for improved drug delivery within the tumor microenvironment. Researchers are actively pursuing the development of advanced nanocarriers with enhanced targeting capabilities, allowing for even more precise and efficient delivery of therapeutic agents to tumor sites. The continued optimization of nanoparticle-based carriers in conjunction with histotripsy holds the potential to maximize treatment efficacy while minimizing systemic toxicity, offering new avenues for personalized cancer care.

The integration of nanotechnology and histotripsy is poised to expand into the realm of combination therapies. The synergistic potential of combining histotripsy with immunotherapeutic agents encapsulated within nanoparticles is a particularly exciting area of exploration. By leveraging the capabilities of histotripsy for precise tissue disruption and localized drug release, researchers aim to further enhance the immune response within the tumor microenvironment, potentially leading to improved outcomes for patients with a variety of solid tumors.

The development of novel imaging techniques that integrate seamlessly with nanoparticle-based contrast agents and histotripsy holds promise for real-time monitoring and assessment of treatment response. Advancements in this area could offer clinicians valuable insights into the immediate effects of therapy, enabling rapid adjustments and ensuring thorough tumor eradication while minimizing damage to healthy tissues.

As the convergence of nanotechnology and histotripsy continues to unfold, the future holds great promise for the refinement and expansion of precision cancer therapy. The ongoing synergy of these advanced technologies stands to reshape the landscape of cancer treatment, offering new avenues for improved patient outcomes and long-term disease control.

The future of cancer treatment lies at the intersection of nanotechnology and histotripsy, where innovative strategies for targeted drug delivery and non-invasive tissue disruption hold the promise of transforming the landscape of cancer therapy. # Future Directions and Challenges

As the field of nanotechnology-based cancer therapies and histotripsy continues to advance, several key areas warrant further exploration and consideration. One of the challenges in nanotechnology-based drug delivery is the need to optimize the synthesis and scale-up production of nanoparticles while ensuring their biocompatibility and stability in biological systems. Additionally, the development of targeted nanocarriers capable of overcoming biological barriers, such as the blood-brain barrier in neuro-oncology, presents an ongoing research frontier.

The integration of histotripsy into clinical practice requires continued refinement of imaging and treatment planning techniques to ensure accurate and precise targeting of tumor tissues. Additionally, the exploration of histotripsy in combination with other treatment modalities, such as chemotherapy or immunotherapy, holds potential for synergistic effects that could further enhance therapeutic outcomes.

Conclusion

In conclusion, the convergence of nanotechnology and histotripsy represents a paradigm shift in cancer treatment, offering the potential for more precise, effective, and less invasive therapeutic strategies. The ability to deliver therapeutics with enhanced specificity to tumor sites while employing non-invasive approaches for tissue disruption has the potential to revolutionize clinical oncology. As ongoing research and clinical trials continue to support the viability and efficacy of these approaches, the future holds great promise for the improved management and outcomes of cancer patients.

The integration of these cutting-edge technologies not only presents opportunities for enhanced treatment efficacy but also underscores the importance of multidisciplinary collaboration among scientists, engineers, clinicians, and other stakeholders in driving innovation in cancer care. As the field continues to evolve, it is essential to foster knowledge exchange and collaboration to translate these advancements into tangible benefits for patients worldwide.

DECLARATIONS

Ethics approval and consent to participate: Not applicable

Consent for publication: All authors give consent for the publication of review article.

Availability of data and material: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Competing interests: None

Funding: This review work was not supported by any funding.

Authors' contributions: AKP conceptualize and written the review. LKT analyzed the content of the article and VA supervised the review process and writing. All authors read and approved the final manuscript.

Acknowledgements: The authors appreciate Dr. Vandana Arora for her valuable input and guidance in the preparation of this review article. We would also like to acknowledge the support provided by Lloyd Institute of Management and Technology, Greater Noida.

References:

1. Prajapati, B G., & Bhattacharya, S. (2023, April 28). Editorial: Biomedical nanotechnology in cancer diagnostics and treatment. https://doi.org/10.3389/fnano.2023.1208544
2. Cuenca, A G., Jiang, H., Hochwald, S N., Delano, M J., Cance, W G., & Grobmyer, S R. (2006, July 18). Emerging implications of nanotechnology on cancer diagnostics and therapeutics. https://doi.org/10.1002/cncr.22035
3. Nanotechnology cancer therapy and treatment. (2017, August 8). Cancer.gov. https://www.cancer.gov/nano/cancer-nanotechnology/treatment
4. Beik, J., Abed, Z., Ghoreishi, F S., Hosseini-Nami, S., Mehrzadi, S., Shakeri-Zadeh, A., & Kamrava, S K. (2016, August 1). Nanotechnology in hyperthermia cancer therapy: From fundamental principles to advanced applications. https://doi.org/10.1016/j.jconrel.2016.05.062
5. Gupta, D., Roy, P., Sharma, R., Kasana, R C., Rathore, P., & Gupta, T K. (2024, January 19). Recent nanotheranostic approaches in cancer research. Springer Science+Business Media, 24(1). https://doi.org/10.1007/s10238-023-01262-3
6. Wang, X., Yang, L., Chen, Z., & Shin, D M. (2008, January 28). Application of Nanotechnology in Cancer Therapy and Imaging. https://doi.org/10.3322/ca.2007.0003
7. Kesharwani, P., Chadar, R., Sheikh, A., Rizg, W. Y., & Safhi, A. Y. (2022). CD44-Targeted Nanocarrier for Cancer Therapy. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.800481
8. Mattheolabakis, G., Milane, L., Singh, A., & Amiji, M M. (2015, September 14). Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to

nanomedicine. https://doi.org/10.3109/1061186x.2015.1052072

9. Hendricks-Wenger, A., Arnold, L., Gannon, J., Simon, A., Singh, N., Sheppard, H., Nagai-Singer, M A., Imran, K M., Lee, K., Clark-Deener, S., Byron, C R., Edwards, M., Larson, M. M., Rossmeisl, J H., Coutermarsh-Ott, S., Eden, K., Dervisis, N., Klahn, S., Tuohy, J., Vlaisavljevich, E. (2022, January 1). Histotripsy Ablation in Preclinical Animal Models of Cancer and Spontaneous Tumors in Veterinary Patients: A Review. https://doi.org/10.1109/tuffc.2021.3110083
10. Xu, Z., Hall, T L., Vlaisavljevich, E., & Lee, F T. (2021, January 1). Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound. https://doi.org/10.1080/02656736.2021.1905189
11. Beik, J., Mehdizadeh, A., & Shakeri-Zadeh, A. (2016, September 1). Ultrasound in Cancer Treatment through Nanotechnology.. https://pubmed.ncbi.nlm.nih.gov/27853719
12. Verma, Y., & Perera Molligoda Arachchige, A. S. (2024). Advances in tumor management: Harnessing the potential of histotripsy. Radiology. Imaging Cancer, 6(3). https://doi.org/10.1148/rycan.230159
13. Yaari, Z., Silva, D D., Zinger, A., Goldman, E., Kajal, A., Tshuva, R., Barak, E C., Dahan, N., Hershkovitz, D., Goldfeder, M., Roitman, J., & Schroeder, A. (2016, November 10). Theranostic barcoded nanoparticles for personalized cancer medicine. https://doi.org/10.1038/ncomms13325
14. Kolhe, S., & Parikh, K. (2012). Application of nanotechnology in cancer: a review. International Journal of Bioinformatics Research and Applications, 8(1/2), 112. https://doi.org/10.1504/ijbra.2012.045954
15. Cho, K., Wang, X., Nie, S., Chen, Z., & Shin, D M. (2008, March 1). Therapeutic Nanoparticles for Drug Delivery in Cancer. https://doi.org/10.1158/1078-0432.ccr-07-1441
16. Feng, L., Dong, Z., Tao, D., Zhang, Y., & Liu, Z. (2017, June 24). The acidic tumor microenvironment: a target for smart cancer nano-theranostics. Oxford University Press, 5(2), 269-286. https://doi.org/10.1093/nsr/nwx062
17. Sutradhar, K B., & Amin, M L. (2014, January 16). Nanotechnology in Cancer Drug Delivery and Selective Targeting. https://doi.org/10.1155/2014/939378
18. Bozzuto, G., & Molinari, A. (2015, February 1). Liposomes as nanomedical devices. https://doi.org/10.2147/ijn.s68861
19. Kumar, P., Gulbake, A., & Jain, S. K. (2012). Liposomes a vesicular nanocarrier: Potential advancements in cancer chemotherapy. Critical Reviews in Therapeutic Drug Carrier Systems, 29(5), 355–419. https://doi.org/10.1615/critrevtherdrugcarriersyst.v29.i5.10
20. Huang, Y., Fan, C., Dong, H., Wang, S., Yang, X., & Yang, S. (2017, March 1). Current applications and future prospects of nanomaterials in tumor therapy. https://doi.org/10.2147/ijn.s127349
21. Singh, P., Pandit, S., Mokkapati, V R S S., Garg, A., Ravikumar, V., & Mijakovic̀, I. (2018, July 6). Gold Nanoparticles in Diagnostics and Therapeutics for Human Cancer. https://doi.org/10.3390/ijms19071979
22. Lim, Z J., Li, J J., Ng, C., Yung, L L., & Bay, B. (2011, July 11). Gold nanoparticles in cancer therapy. https://doi.org/10.1038/aps.2011.82
23. Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017, May 9). Rethinking cancer nanotheranostics. https://doi.org/10.1038/natrevmats.2017.24
24. Chavda, V P., Khadela, A., Shah, Y., Postwala, H., Balar, P C., & Vora, L K. (2023, January 1). Current status of Cancer Nanotheranostics: Emerging strategies for cancer management. https://doi.org/10.7150/ntno.82263
25. Cancer imaging. Cancer imaging - Latest research and news. (2024, May 23). Springer Nature. https://www.nature.com/subjects/cancer-imaging
26. Sajja, H K., East, M P., Mao, H., Wang, Y A., Nie, S., & Yang, L. (2009, March 1).

Development of Multifunctional Nanoparticles for Targeted Drug Delivery and Noninvasive Imaging of Therapeutic Effect. https://doi.org/10.2174/157016309787581066

27. Kulkarni, A., Rao, P R R., Natarajan, S K., Goldman, A., Sabbisetti, V., Khater, Y., Korimerla, N., Chandrasekar, V., Mashelkar, R A., & Sengupta, S. (2016, March 29). Reporter nanoparticle that monitors its anticancer efficacy in real time. https://doi.org/10.1073/pnas.1603455113
28. Thomas, R G., Park, I K., & Jeong, Y Y. (2013, July 31). Magnetic Iron Oxide Nanoparticles for Multimodal Imaging and Therapy of Cancer. https://doi.org/10.3390/ijms140815910
29. Hilger, I., & Kaiser, W A. (2012, September 1). Iron oxide-based nanostructures for MRI and magnetic hyperthermia. https://doi.org/10.2217/nnm.12.112
30. Sumer, B D., & Gao, J. (2008, April 1). Theranostic nanomedicine for cancer. https://doi.org/10.2217/17435889.3.2.137
31. Wang, L., Chuang, M., & Ho, J A. (2012, August 1). Nanotheranostics – a review of recent publications. https://www.dovepress.com/getfile.php
32. Zhang, Y., Li, M., Gao, X., Chen, Y., & Liu, T. (2019, December 1). Nanotechnology in cancer diagnosis: progress, challenges and opportunities. https://doi.org/10.1186/s13045-019-0833-3
33. Pasinszki, T., Krebsz, M., Tung, T., & Lošić, D. (2017, August 20). Carbon Nanomaterial Based Biosensors for Non-Invasive Detection of Cancer and Disease Biomarkers for Clinical Diagnosis. https://doi.org/10.3390/s17081919
34. Fan., Cao, D., Meiqun, Y., Wang, Y., Gong, Y., & Tao. (2023, August 7). Nanomedicine in cancer therapy - Signal Transduction and Targeted Therapy. https://www.nature.com/articles/s41392-023-01536-y
35. Han, H S., & Choi, K Y. (2021, March 16). Advances in Nanomaterial-Mediated Photothermal Cancer Therapies: Toward Clinical Applications. https://doi.org/10.3390/biomedicines9030305
36. Liao, J., Qi, T., Chu, B., Peng, J., Luo, F., & Qian, Z. (2014, January 1). Multifunctional Nanostructured Materials for Multimodal Cancer Imaging and Therapy. https://doi.org/10.1166/jnn.2014.9049
37. Dadwal, A., Baldi, A., & Narang, R K. (2018, July 25). Nanoparticles as carriers for drug delivery in cancer. https://doi.org/10.1080/21691401.2018.1457039
38. Yan, S., Zhao, P., Yu, T., & Gu, N. (2019, August 1). Current applications and future prospects of nanotechnology in cancer immunotherapy. https://doi.org/10.20892/j.issn.2095-3941.2018.0493
39. Wang, B., Zhang, Y., & Yin, X. (2023, December 1). Advances in tumor immunomodulation based on nanodrug delivery systems. https://doi.org/10.3389/fimmu.2023.1297493
40. Li, D., Ouyang, K., Xu, X., Xu, L., Wen, C., Zhou, X., Qin, Z., Zhang, X., Sun, W., & Liang, Y. (2021, May 12). Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing. https://doi.org/10.3389/fgene.2021.673286
41. Kim, D., Le, Q., Wu, Y., Park, J., & Oh, Y. (2020, December 18). Nanovesicle-Mediated Delivery Systems for CRISPR/Cas Genome Editing. https://doi.org/10.3390/pharmaceutics12121233
42. Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A M., Schubert, M S., Friedmann-Morvinski, D., Cohen, Z., Behlke, M A., Lieberman, J., & Peer, D. (2020, November 20). CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. https://doi.org/10.1126/sciadv.abc9450
43. Draz, M S., Fang, B., Zhang, P., Hu, Z., Gu, S., Weng, K C., Gray, J W., & Chen, F F. (2014, January 1). Nanoparticle-Mediated Systemic Delivery of siRNA for Treatment of Cancers

and Viral Infections. https://doi.org/10.7150/thno.9404
44. Choi, C H J., Zhang, L., & Choi, C H J. (2018, May 10). Efficient siRNA delivery with non-cationic carriers. https://doi.org/10.1038/s41551-018-0240-z
45. Gulino, A. (2012, July 1). Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. https://doi.org/10.2147/ijn.s23696
46. Chai, X., Yi, D., Chen, S., Zhao, J., & Li, L. (2023, April 12). A Remotely Controlled Nanosystem for Spatiotemporally Specific Gene Regulation and Combinational Tumor Therapy. https://doi.org/10.1002/anie.202217702
47. Chen, X., Wang, S., Chen, Y., Xin, H., Zhang, S., Wu, D., Xue, Y., Zha, M., Li, H J., Li, K., Gu, Z., Wei, W., & Yuan, P. (2023, May 15). Non-invasive activation of intratumoural gene editing for improved adoptive T-cell therapy in solid tumours. https://doi.org/10.1038/s41565-023-01378-3
48. Herrmann, I K., & Rösslein, M. (2016, January 1). Personalized medicine: the enabling role of nanotechnology. https://doi.org/10.2217/nnm.15.152
49. Nassar, S F., Raddassi, K., Ubhi, B K., Doktorski, J., & Abulaban, A. (2020, September 9). Precision Medicine: Steps along the Road to Combat Human Cancer. https://doi.org/10.3390/cells9092056
50. Hendricks-Wenger, A., Hutchison, R., Vlaisavljevich, E., & Allen, I C. (2021, May 31). Immunological Effects of Histotripsy for Cancer Therapy. https://doi.org/10.3389/fonc.2021.681629
51. Dwivedi, A K., Sengottayan, V K., & Goel, A. (2010, January 1). A minimally invasive non-thermal ablative modality for prostate: Histotripsy. https://doaj.org/article/b17748219b3d4db79a1c8cdcf4226fef
52. Zubair, M., & Smith, J M. (2017, August 1). Updates in Minimally Invasive Cardiac Surgery for General Surgeons. https://doi.org/10.1016/j.suc.2017.03.002
53. Roberts, W. W. (2014). Development and translation of histotripsy: Current status and future directions. Current Opinion in Urology, 24(1), 104–110. https://doi.org/10.1097/mou.0000000000000001
54. Pepple, A., Guy, J L., McGinnis, R J., Felsted, A E., Song, B J., Hubbard, R., Worlikar, T., Garavaglia, H., Dib, J., Chao, H., Boyle, N., Olszewski, M., Xu, Z., Ganguly, A., & Cho, C S. (2023, January 23). Spatiotemporal local and abscopal cell death and immune responses to histotripsy focused ultrasound tumor ablation. https://doi.org/10.3389/fimmu.2023.1012799
55. McCarthy, P M., Valdera, F A., Smolinsky, T R., Adams, A., O'Shea, A E., Thomas, K K., Decar, S V., Carpenter, E L., Tiwari, A., Myers, J M., Hale, D F., Vreeland, T J., Peoples, G E., Stojadinovic, A., & Clifton, G T. (2023, March 7). Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials. https://doi.org/10.3389/fimmu.2023.1090533
56. Vlaisavljevich, E., Durmaz, Y Y., Maxwell, A D., El-Sayed, M., & Xu, Z. (2013, January 1). Nanodroplet-Mediated Histotripsy for Image-guided Targeted Ultrasound Cell Ablation. https://doi.org/10.7150/thno.6717
57. Schade, G R., Keller, J., Ives, K., Cheng, X., Rosol, T J., Keller, E., & Roberts, W W. (2012, November 5). Histotripsy focal ablation of implanted prostate tumor in an ACE-1 canine cancer model. https://www.auajournals.org/doi/10.1016/j.juro.2012.07.006
58. Triesscheijn, M., Baas, P., Schellens, J H., & Stewart, F. (2006, October 1). Photodynamic Therapy in Oncology. https://doi.org/10.1634/theoncologist.11-9-1034
59. Khokhlova, T D., & Hwang, J H. (2016, January 1). HIFU for Palliative Treatment of Pancreatic Cancer. https://doi.org/10.1007/978-3-319-22536-4_5

60. Osterweil, N. (2023, October 26). Histotripsy Targets Unresectable Liver Tumors With Ultrasound. https://www.obroncology.com/article/histotripsy-targets-unresectable-liver-tumors-with-ultrasound
61. Jackson, A., Pathak, R., DeSouza, N M., Liu, Y., Jacobs, B K M., Litière, S., Urbanowicz-Nijaki, M., Julié, C., Chiti, A., Theysohn, J., Ayuso, J R., Stroobants, S., & Waterton, J C. (2023, July 12). MRI Apparent Diffusion Coefficient (ADC) as a Biomarker of Tumour Response: Imaging-Pathology Correlation in Patients with Hepatic Metastases from Colorectal Cancer (EORTC 1423). https://doi.org/10.3390/cancers15143580
62. Hall, T L., Hempel, C R., Wojno, K., Xu, Z., Cain, C A., & Roberts, W W. (2009, October 5). Histotripsy of the prostate: dose effects in a chronic canine model. http://goldjournal.net/retrieve/pii/S009042950900586X
63. Wang, Y., Qin, Z., Wang, Y., Chen, C., Wang, Y., Meng, X., & Song, N. (2018, January 17). The role of radical prostatectomy for the treatment of metastatic prostate cancer: a systematic review and meta-analysis. https://doi.org/10.1042/bsr20171379
64. Wheat, J C., Hall, T L., Hempel, C R., Cain, C A., Xu, Z., & Roberts, W W. (2010, January 1). Prostate Histotripsy in an Anticoagulated Model. https://doi.org/10.1016/j.urology.2009.09.021
65. Bae, K H., Chung, H J., & Park, T G. (2011, April 1). Nanomaterials for Cancer Therapy and Imaging. https://doi.org/10.1007/s10059-011-0051-5
66. Castle, J., Butts, M., Healey, A., Kent, K., Marino, M., & Feinstein, S B. (2012, November 30). Ultrasound-mediated targeted drug delivery: recent success and remaining challenges. https://journals.physiology.org/doi/10.1152/ajpheart.00265.2012
67. Zhou, Q., Chen, Z., Wáng, Y X J., Yang, F., Lin, Y., & Liao, Y. (2014, January 1). Ultrasound-Mediated Local Drug and Gene Delivery Using Nanocarriers. https://doi.org/10.1155/2014/963891
68. Duan, L., Li, Y., Jin, J., Yang, F., Liu, D., Hu, K., Wang, Q., Yue, Y., & Gu, N. (2020, January 1). Micro/nano-bubble-assisted ultrasound to enhance the EPR effect and potential theranostic applications. https://doi.org/10.7150/thno.37593
69. Wang, Y., Sun, S., Zhang, Z., & Shi, D. (2018, March 5). Nanomaterials for Cancer Precision Medicine. https://doi.org/10.1002/adma.201705660
70. Cormode, D P., Skajaa, T., Fayad, Z A., & Mulder, W J M. (2009, July 1). Nanotechnology in Medical Imaging. https://doi.org/10.1161/atvbaha.108.165506
71. Edis, Z., Wang, J., Waqas, M., Ijaz, M., & Ijaz, M. (2021, February 1). Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives. https://doi.org/10.2147/ijn.s289443
72. Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020, August 20). Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. https://doi.org/10.3389/fmolb.2020.00193
73. Lake, A M., Hall, T L., Kieran, K., Fowlkes, J B., Cain, C A., & Roberts, W W. (2008, September 5). Histotripsy: minimally invasive technology for prostatic tissue ablation in an in vivo canine model. http://goldjournal.net/retrieve/pii/S0090429508001064
74. Green, H., Crockett, S., Martyshkin, D., Singh, K., Grizzle, W., Rosenthal, E L., & Mirov, S. (2014, November 1). A histological evaluation and in vivo assessment of intratumoral near infrared photothermal nanotherapy-induced tumor regression. https://doi.org/10.2147/ijn.s60648